摘要
目的探讨附子强心方辅助治疗慢性心力衰竭(CHF)患者的疗效。方法选择2018年7月—2020年6月本院收治的CHF患者96例作为研究对象,随机数表法分为西药组和中药组两组,每组各48例。西药组采用常规西药治疗,中药组采用在常规西药治疗的基础上联合应用附子强心方治疗。比较两组疗效、治疗前、治疗1个月后心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、心衰标志物[血清可溶性生长刺激表达基因2蛋白(sST2)、脑钠肽(BNP)]、不良反应(胃肠道反应、皮疹、头晕)发生率。结果中药组治疗总有效率(91.67%)高于西药组(75.00%)(P<0.05);治疗1个月后,两组LVEF均升高,中药组高于西药组,两组LVEDD、LVESD均下降,中药组低于西药组(P<0.05);治疗1个月后,两组血清sST2、BNP水平均下降,中药组低于西药组(P<0.05);两组不良反应发生率比较无明显差异(P>0.05)。结论附子强心方辅助治疗CHF患者疗效显著,可降低心衰标志物水平,改善心功能,且安全性高。
Objective To explore the value of Fuzi Qiangxin decoction in the adjuvanttreatment of patients with chronic heart failure(CHF).Methods A total of 96 patients with CHF admitted to our hospital from July 2018 to June 2020 were enrolled as study and they were randomly divided into western medicine group and Chinese medicine group according to number table method,with 48 patients in each group.The western medicine group was treated with conventional western medicine,while the traditional Chinese medicine group was treated with Fuzi Qiangxin decoction on the basis of conventional western medicine.The curative effect,cardiac function(including left ventricular ejection fraction,LVEF;left ventricular end diastolic diameter,LVEDD;Left ventricular end systolic diameter,LVESD)and markers of heart failure(serum soluble growth stimulation expression gene 2 protein,sST2;brain natriuretic peptide,BNP)before and after the treatment,and the incidence of adverse reactions(gastrointestinal reaction,skin rash,dizziness)of the two groups were compared.Results The total effective rate of TCM group was 91.67%,which higher than 75.00%of western medicine group(P<0.05).After 1 month of treatment,LVEF increased in both groups and the TCM group was higher than the western medicine group;LVEDD and LVESD decreased in both groups and TCM group was lower than western medicine group(P<0.05).After 1 month of treatment,serum SST2 and BNP levels in both groups decreased,and those in TCM group were lower than those in western medicine group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Fuzi Qiangxin decoction has significant efficacy in the adjuvant treatment of CHF patients,it could reduce the level of heart failure markers,improve cardiac function,and has high safety.
作者
赵艺
ZHAO Yi(Cardiovascular medicine department,people's hospital of Xinzheng city,Xinzheng,Henan,451100,China)
出处
《齐齐哈尔医学院学报》
2021年第18期1607-1609,共3页
Journal of Qiqihar Medical University
关键词
附子强心方
慢性心力衰竭
疗效
心功能
心衰标志物
不良反应发生率
Fuzi qiangxin decoction
Chronic heart failure
Efficacy
Cardiac function
Heart failure marker
Incidence of adverse reaction
